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THE HUMAN CELL LINE CCRF-CEM
was derived by Foley et al. (1965) from
the peripheral blood of a patient with
acute lymphoblastic leukaemia (ALL).
When tested by Norman & Thompson
(1977) CCRF-CEM was only partially
sensitive to glucocorticoids, but Clone C7,
isolated from the parental cell line, was
lysed by pharmacological concentrations
of glucocorticoids. The availability of a
steroid-sensitive human lymphoid cell line
made it possible to study interactions
between steroids and other chemothera-
peutic drugs under conditions more appro-
priate to their clinical usage. Some pre-
liminary results obtained with CEM-C7
cells have already been described (Norman
et al., 1978). This paper presents the results
of further investigations into the inter-
action of prednisolone with drugs used in
the treatment ofALL. The drugsusedwere
6-mercaptopurine (MP), methotrexate
(MTX), cytosine arabinoside (Ara-C) and
daunomycin (DMN).
CEM-C7 cells were maintained in con-
tinuous culture in Medium RPMI 1640
supplemented with 10% foetal calf serum
(Flow Laboratories). In fresh medium cell
growth was exponential between 105 and
5 x 106 cells/ml. Solutions of prednisolone
and other drugs (Sigma Chemical Co.)
were prepared fresh for each experiment.
Prednisolone was added to cell suspensions
from a stock solution in 10% or 1%
ethanol; an equivalent volume of ethanol
was added to control cells. Ara-C and
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DMN were readily soluble in culture
medium, but MP and MTX required
50-100mM NaOH in stock solutions.
Twenty-four hours before the start of
each experiment, an aliquot of CEM-C7
cells was centrifuged (500 g av.) and re-
suspended in fresh medium at concentra-
tions of 1-5x 105 cells per ml. The cells
were first treated for 24 h with predni-
solone (10-6M) alone, since previous work
(Harmon et al., 1979) demonstrated a lag
period ofabout 20 h before steroid-induced
cell killing was observed. The cells were
then cultured for a further 24 h in the
presence of prednisolone (10-6M) plus one
of the drugs in a range of concentrations.
After drug treatment cell suspensions
were centrifuged, washed once with an
equal volume of drug-free medium and
resuspended in more fresh medium for
counting (Coulter Counter, model DN).
The cells were diluted for plating in
TABLE.-Interaction between prednisolone
and other antileukaemic drugs. Definition
ofterms
S A =Fractionofthe cellpopulationsurviving
exposure to prednisolone
SB= Fraction ofthe cellpopulation surviving
exposure to second drug
SAB =Fraction ofthe cellpopulationsurviving
exposure to both drugs
SA.SB=Predicted cell survival in the presence
of both drugs
SAB/SA.SB=Interaction index (>1 indicate an-
tagonism = I when drugs act independ-
ently, <1 indicate synergism)R. M. GLEDHILL AND Al. R. NORMAN
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FIG. 1.-Representation of results obtained for the combination of prednisolone (10-6M) with anti-
leukaemic drugs. The survival curves (% of control) are given for the drug alone, SB (0) and in
combination with prednisolone, SAB (0). These curves are compared with the predicted cell
survival SA.SB (A). For definition of terms see Table.
agarose gels at between 250 and 2,500 cells
per dish (Norman et al., 1978). Sal Mat
fibroblasts (from a patient with Lesch-
Nyhan syndrome) were used as the feeder
layer. Highest cloning efficiencies were
obtained in conditions of high humidity
with a feeder layer of actively growing
fibroblasts. The dishes were incubated
immediately above a layer of water in a
perspex box within a CO2 incubator
maintained at 80% humidity. Cloning
efficiency varied between experiments,
with a mean of 530.
The terms used to describe the drug
interactions are defined in the Table. If
two drugs act quite independently, their
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FIG. 2.-Mean interaction indices for a range of concentrations of MTX (U, data from 3 exp.), DMN
(O, data from 5 exp.), MP (E, data from 2 exp.) and Ara-C (0, data from 3 exp.).
combined toxicity (SA.SB) can be pre-
dicted from their individual toxicities
(SA and SB). Comparison can then be
made between predicted values and the
actual survival measured in the presence
of both drugs (SAB).
There was some variation between
experiments in the number of cells killed
by 1O-6M prednisolone. This variation was
due in part to variation in cloning effi-
ciency; conditions favouring high cloning
efficiency increased cell survival on treat-
ment with steroid. Effects ofthis sort have
been observed with other cytotoxic drugs
(Weizsaecker & Deen, 1980) and the
effect of cloning efficiency on steroid-
induced killing is now under investigation.
Fig. 1 shows the results from one
experiment in which prednisolone was
combined with the 4 antileukaemic drugs.
Repeatedly DMN and MTX showed no
evidence of clear or consistent interaction
with prednisolone, though interaction
between DMN and prednisolone varied
between mild synergism (Fig. 1) and
antagonism (not shown). Results for
MP consistently indicated antagonism
between MP and prednisolone, confirming
the antagonism observed by Norman et
al. (1978) at a single drug concentration.
A similar antagonism was observed be-
tween prednisolone and Ara-C.
In order to facilitate comparison of
results from repeat experiments, the
ratio SAB/SA.SB (interaction index) was
calculated (Fig. 2). The mean interaction
indices for both DMN and MTX were
close to unity, indicating that, for the
protocol used here, the action of DMN and
MTX on CEM-C7 cells was independent
of prednisolone.
Interaction indices for MP and Ara-C
demonstrated antagonism. Theinteraction
index for each drug was approximately
constant across the concentration range
used, despite large differences in degree
of drug-induced killing. For each separate
experiment, where survival with predni-
solone (SA) is constant (k1) a constant
value for SAB/SA.SB (k2) means that
SAB =k2.k1.SB (1)
The antagonism (SAB-SA.SB) then be-
comes
k2.klSB-kl.SB
= SB (k2.k1-k1) (2)
i.e. the antagonism is directly proportional
to SB (cell survival in the presence of MP
or Ara-C). Therefore, under conditions
where the interaction index is constant,
equation (2) shows that antagonism will
be most evident at low concentrations of
B, where SB is highest. When large num-
bers of cells are killed by B (low SB) there
will be a corresponding decrease in the
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FIG. 3.-The effect of a non-toxic concentra-
tion of Ara-C on CEM-C7 cell survival in
the presence of prednisolone. Cells were
exposed to prednisolone for 48 h with (0)
or without (0) Ara-C (10-8M) during the
final 24 h of treatment.
number of cells which can be protected,
and the value ofSAB-SA.SB will necessarily
be small.
Fig. 3 shows that Ara-C antagonizes
prednisolone-induced cell killing, rather
than the reverse. The low concentration
(10-8M) used in this experiment had no
measurable effect on cell viability, but it
still decreased cell killing by prednisolone
(0.5-5 x 10-6M).
When the DNA content of CEM-C7 cells
was measured by flow cytofluorimetry,
combination of prednisolone with MP
(Norman et al., 1978) or with Ara-C
(Gledhill & Norman, unpublished) accord-
ing to the above protocol, increased the
number of cells in early S. The S-phase
block predominated over the effect of
prednisolone alone, which was to increase
the number of cells in G1.
On the basis of results obtained so far,
a working hypothesis for the antagonism
of drugs to steroid-induced cell killing
has been formulated. It has two basic
tenets: (i) MP and Ara-C cause inhibition
of DNA synthesis which is to some extent
reversible, even at drug concentrations
causing considerable cell death; (ii) cells
blocked in early S are protected from the
lethal effects of steroid. In the protocol
used here, prednisolone is removed at the
same time as MP or Ara-C, so cells that
survive the S-phase block will be able to
resume growth.
All 4 of the drugs used are capable of
inhibiting DNA synthesis, but precise
mechanisms for their cytotoxicity are not
yet established (Chabner et al., 1975;
Bertino, 1979; Nelson et al., 1975; Kufe
et al., 1980). The failure of DMN and
MTX definitely to antagonize prednisolone
killing could be explained in terms of the
above hypothesis, if their effects on DNA
synthesis were irreversible. DMN binds
directly to DNA (Chabner et al., 1975)
and MTX binds strongly to dihydrofolate
reductase (Goldman et al., 1968) so the
effects of DMN and MTX might be less
reversible by washing than those of MP
and Ara-C. After intracellular phosphory-
lation, MP and Ara-C are, respectively,
competitive inhibitors of de novo ribo-
nucleotide biosynthesis and DNA poly-
merase (Tidd & Paterson, 1974; Woodcock
et al., 1979). Graham & Whitmore (1970)
and Jones et al. (1976) have reported al-
most total inhibition of DNA synthesis by
non-lethal concentrations of Ara-C, so the
antagonism of prednisolone killing by
10-8M Ara-C (Fig. 3) may be due to non-
lethal inhibition of DNA synthesis.
Antagonistic interactions of the type
described here may have important impli-
cations for the design of ALL chemo-
therapy schedules that involve steroids
and cell-cycle-specific drugs. Further in-
vestigations of the mechanism of this
antagonism include experiments in vitro
with different protocols designed to in-
crease the sensitivity of leukaemic cells to
steroid.
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